Voting Results from the General Meeting Held on January 18, 2019
Daix (France), January 21 st , 2019 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced, in accordance with the terms of Article R. 225-106-1 of the French "Code de commerce", the voting results of its General Meeting held on January 18 th , 2019.
The Company's shareholders met during an Extraordinary and Ordinary General Meeting on January 18 th , 2019 at the Hôtel Océania le Jura (Salon Pasteur - 14, avenue Foch, 21000 Dijon), following a notice of the meeting published in the "Bulletin des Annonces Légales Obligatoires" on December 28 th , 2018 and by letters addressed to the registered shareholders.
The meeting was chaired by Mr. Frédéric Cren, Co-founder, Chief Executive Officer and Chairman of Inventiva.
Total number of shares: 22,276,977
Number of voting rights: 22,230,675
Number of shares held by shareholders present or represented by proxy or submitted by postal voting forms: 15,549,743
Number of voting rights held by shareholders present or represented: 9,978,681
Proportion of represented capital: 69.95%
| Shareholders | Voting Rights | Shares | Total number of voting rights | ||
| Simple | Double | ||||
| Present or proxies | 6 | 100 130 | 19 545 000 | 9 872 630 | 19 645 130 |
| Proxies to the President | 16 | 106 051 | 106 051 | 106 051 | |
| Postal voting forms | 10 | 5 571 062 | 5 571 062 | 5 571 062 | |
| TOTAL | 32 | 5 777 243 | 19 545 000 | 15 549 743 | 25 322 243 |
| Resolution | Voting Results | Voted for | Voted against | Abstention | Off vote | Number of voting rights | ||
| Number of voting rights | % | Number of voting rights | % | Number of voting rights | ||||
| Resolution 1 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 2 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 3 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 4 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 5 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 6 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 7 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 8 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 9 - AGE | Adopted | 21 952 124 | 86.69% | 3 370 119 | 13.31% | 0 | 25 322 243 | |
| Resolution 10 - AGE | Adopted | 21 926 385 | 86.59% | 3 395 858 | 13.41% | 0 | 25 322 243 | |
| Resolution 11 - AGE | Adopted | 22 208 584 | 87.70% | 3 113 659 | 12.30% | 0 | 25 322 243 | |
| Resolution 12 - AGO | Adopted | 22 317 839 | 88.14% | 3 004 404 | 11.86% | 0 | 25 322 243 | |
About Inventiva : www.inventivapharma.com
Inventiva is a biopharmaceutical company specialized in the development of product candidates interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva's research engine has the potential to open up novel therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities, such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies, AbbVie and Boehringer Ingelheim, in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis, respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties any approved products resulting from the partnerships.
Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.
Contacts
| Inventiva Frédéric Cren President & CEO info@inventivapharma.com + 33 3 80 44 75 00 | Brunswick Julien Trosdorf / Yannick Tetzlaff Media relations inventiva@brunswickgroup.com + 33 1 53 96 83 83 | LifeSci Advisors Chris Maggos Investor relations chris@lifesciadvisors.com + 41 79 367 6254 |
Attachment
